Cisplatin is a widely used chemotherapy drug in the treatment of pediatric solid tumors, but it is associated with significant rates of ototoxicity (medication-induced hearing loss). A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. This study estimates the potential economic impact of this test. Assuming that an alternative, non-preferred, medication to cisplatin exists that it is as efficacious as cisplatin but without the risk of hearing loss, and that the alternative treatment is no more expensive than current practice, we have estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71 168 in societal costs per tested patient. This translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.
Introduction
Cisplatin has a key role in the treatment of pediatric solid tumors 1 and is one of the most commonly used cytotoxic agents in the treatment of a variety of solid malignant tumors. 2 However, just as the therapeutic value of cisplatin is well recognized, so is the fact that this drug is associated with ototoxicity. Estimates of the incidence of bilateral hearing loss due to ototoxicity are 41-61% in children. [3] [4] [5] [6] Cisplatin-induced hearing loss is permanent and imposes significant health-care and societal costs. 7 A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. 8 About one third of children are expected to test positive and those children are almost certain to develop serious ototoxicity if treated with cisplatin in standard dosage (likelihood of over 98%). This test, however, cannot be used to rule out the risk of ototoxicity as about half of those who test negative will still develop serious ototoxicity.
The purpose of this study was to assess the potential economic impact of implementing this genetic test for ototoxicity susceptibility. The study was composed of three parts. First, the potential impact of the new test on ototoxicity incidence was estimated. Second, health-care and non-health-care costs associated with the various levels of hearing loss were estimated. Finally, the cost estimates and potential change in ototoxicity incidence were combined to determine the possible economic impact of the genetic test. Consideration was also given to the impact of the test on quality of life to provide context to the cost figures.
The current assessment starts with the assumption that alternative medications to cisplatin exist that are as efficacious as cisplatin but without the risk of hearing loss. We also assume that the alternative medications are, for whatever reason, not the preferred treatment option and therefore should only be used in cases where there is a very high probability of serious cisplatin-induced ototoxicity. Finally, we assume that the alternative medications or treatments are not more expensive than current practice. In reality, the availability and efficacy of alternatives to cisplatin vary by type of cancer and are changing over time (a description of the current status of alternatives is provided). These assumptions were necessary to avoid the issue of trade-offs between treatment efficacy, cost and risk of hearing loss. These tradeoffs are an important subject, but are not the focus of this paper. Our focus is on measuring the maximum potential value of the new test. In the following sections, the methods for the economic evaluation are outlined and the results are presented. We then describe the status of alternatives to cisplatin and finally, we discuss the findings in light of current research on alternatives to cisplatin and on ototoprotectants and provide some concluding remarks.
Materials and methods

The test
The cisplatin genetic test uses DNA purified from saliva or blood. The DNA sample is collected by a physician or a nurse in a simple-to-use collection device (that is, Oragene collection device), and then run on a genotyping platform using a highly validated assay. The results will be validated to very high standards-as is the common practice for all clinical genotyping in accredited clinical laboratories (that is, Clinical Laboratory Improvement Amendments standards). Currently, the test costs are B$150-250 per test-but this could change with higher utilization and technological advances.
Potential economic impact estimation
We first estimated the potential impact of the genetic test on the incidence of ototoxicity. This is the difference between the observed incidence and the expected incidence had the test been administered to all children before treatment started. The calculations of those two incidence rates are based on the information from two research cohorts of pediatric cancer patients in Canada that were recruited for the purposes of developing the genetic test (n ¼ 166). The incidence is defined in terms of the Common Terminology Criteria for Adverse Events grading scale. The Common Terminology Criteria for Adverse Events grading scale has four grades of hearing loss (1 through 4). This first step, therefore, resulted in an observed distribution of cases between no hearing loss and the four grades of hearing loss and an expected distribution associated with the test. Since the positive predictive value of the test is 498%, we ignored the small proportion of false positives in our calculations of impact (that is, children that were treated unnecessarily with an alternative medication).
In the second step, costs of ototoxicity were estimated. The costs related to hearing loss are assumed to be independent of, and additive to, any other costs, throughout lifetime, associated with the cancer. Costs of ototoxicity include treatment costs and, because treatment does not restore full hearing, costs associated with adjusting to life with hearing impairment and with limitations imposed by the hearing impairment. Costs vary by degree of hearing loss, age and age at diagnosis. However, because the degree of hearing loss and average age at diagnosis vary by type of cancer, we did a separate analysis for the five most common types of pediatric cancer where cisplatin is considered standard first-line treatment: osteosarcoma, germ cell tumors, brain tumors, neuroblastoma and hepatoblastoma (these five diagnoses account for 161 of 166 patients in the research cohorts).
The analysis was based on four categories of age reflecting different needs: under 6 years old; 6-11 years old; 12-18 years old; and over 18 years old. For simplicity, we assumed that annual costs are similar within these categories (for example, the annual cost of treating a case of grade 2 hearing loss is the same for every year between 6 and 11). We also used these same categories to differentiate the age of diagnosis.
To calculate the costs by grade of hearing loss for each type of cancer, we used the distribution of age at diagnosis for those who would have tested positive and developed grade 3 or 4 hearing loss (using the Common Terminology Criteria for Adverse Events grading scale). We used this distribution because those are the children that we expect will be most directly affected by the introduction of the new test.
Costs were obtained from two sources. First, for children and adolescents, costs figures were provided by a registered clinical audiologist at British Columbia Children's Hospital specializing in the treatment of ototoxicity, with validation from two colleagues in different organizations. These cost figures included treatment costs as well as costs associated with adaptation to life with hearing impairment. Second, for costs in adulthood of hearing loss acquired before age 19 years, we conducted a search in Medline using the search terms: 'hearing loss,' 'children,' 'treatment' and 'societal costs' (search strategy details available upon request). Abstracts were reviewed and articles addressing the cost of such hearing loss were retrieved. The search produced 302 abstracts and, based on relevancy, 5 full papers were used in constructing our model.
On the basis of the cost information, we calculated a present value cost per grade of hearing loss by type of cancer. To obtain present values, we used a discount rate of 2.4% which is the current real interest rate on long-term Government of Canada bonds (nominal rate of 4% minus inflation rate of 1.6%). 9 Since a real discount rate was used, future costs figures were not adjusted for inflation.
The final step in the estimation of the potential economic impact involved calculating the difference between the expected costs related to ototoxicity for the research cohorts and the expected costs had the test been administered to Impact of a genetic test for cisplatin ototoxicity each of these children before treatment started and medication switched for those that tested positive. To extrapolate this difference at the population level, we used the average number of new cases per year in British Columbia and Canada and applied historical mortality rates by type of cancer.
Results
Potential impact of the genetic test on the incidence of pediatric cisplatin-induced ototoxicity With the assumption that alternative medications exist that would avoid ototoxicity, and that these alternatives are not the preferred treatment and would only be given to those children that tested positive, we estimate a reduction in the incidence of grades 2, 3 and 4 hearing loss from 64.6 to 33%. The incidence of severe hearing loss (grades 3 and 4 only) would decrease from 57.8 to 31.1%. Incidence rates under these assumptions, by grades of hearing loss, for pediatric cancer patients for whom cisplatin is considered first-line therapy, are presented in Table 1 .
If we conservatively assume that alternative medications would reduce the risk of ototoxicity in half and that again these alternatives are not the preferred treatment and thus are only used with those children that tested positive, the reduction in grades 2 and above hearing loss is from 64.6 to 48.7% and the reduction in the incidence of severe hearing loss (grades 3 and 4) is from 57.8 to 44.4%. The resulting incidence estimates under these assumptions are presented in Table 2 .
Estimation of the costs associated with the various grades of ototoxicity Cost of ototoxicity depends on the grade of hearing loss, the age and the age of hearing loss onset. Children with grade 1 or lesser hearing loss have minimal problems and are essentially monitored for change in status. Children with grade 2 hearing loss are monitored more closely than grade 1 and may need some minimal assistance. Children with grade 3 or 4 have severe hearing impairment and the associated costs (and negative impact on quality of life) are considerably higher.
Costs until age 18 years are composed mainly of healthcare costs and education costs. After age 18 years, the main costs are lost productivity (B85% of total costs after age 18 years) and health-care services (B10% of total annual costs). 10 As hearing loss of grade 2 or lower has very limited impact on the societal functionality of individuals, we found no evidence that such hearing loss poses any additional costs to the health-care system or causes any loss of productivity in adulthood; therefore, no costs were assigned to these grades after age 18 years. For severe hearing loss (grade 3 or 4), lost productivity was measured as the expected earning differential between adults with such hearing loss and all adults. The differential is estimated at 33% of average earnings for ages 18-44 years and at 13% for ages 45-65 years. 10 Average annual earnings in Canada were $46 575 for men and $30 631 for women (2010 dollars) (2007 figures adjusted to 2010 using core Consumer Price Index increases from Bank of Canada 9 ). 11 On the basis of our research cohorts, 60% of pediatric cancer patients for our five types of cancers were males and 40% females. Using this ratio, we calculated an estimated annual loss of productivity of $13 265 for ages 18-44 years and $5226 for ages 45-65 years. The health-care costs after age 18 years are mostly related to hearing aids, so we used an annual estimated health-care cost of $766.50 for ages 18-65 years (from Appendix A)-which works out to be about 15% of total costs for ages 45-65 years and 6% for ages 18-44 years. For this study, we ignored costs after age 65 years for two reasons: first, after age 65 years, productivity losses are likely to be small and second, because this genetic test focuses on pediatric patients, the discounting of impacts after age 65 years renders these small amounts essentially inconsequential to the total cost estimates.
The estimated present value total health-care costs for grade 2 hearing loss vary between $298 and $1269, depending on the type of cancer. For these same hearing losses, the estimated present value total societal costs vary between $3465 and $11 626. For grade 3 or 4 hearing loss, the estimated health-care costs range from $21 018 to $39 176 and the total societal costs are estimated at between $445 446 and $562 198 (detailed cost figures are presented in Appendix A). The total present value estimated costs by grade and type of cancer are presented in Table 3 .
Estimation of the economic impact of the new genetic test
Using a figure of $250 for the cost of the test (High end of the current range for test cost), the potential expected savings generated by the administration of the test to every Table 3 ). Those figures are similar to the estimate of $383 000 (2003 USD) from the Centers for Disease Control and Prevention in the United States. 12 The test is expected to reduce the incidence of grade 3 or 4 hearing losses from 57.8 to 31.1%, a reduction of 26.7% (assuming that the alternative treatments eliminate ototoxicity). This expected reduction in incidence alone, on the basis of a total cost of B$450 000 per case, leads to a reduction of the average cost of ototoxicity of about $120 000.
Using the mortality rates for each type of cancer, we can express the expected savings in terms of patient tested (as opposed to surviving patient). The new test, using a test cost figure of $250, is expected to produce potential present value cost savings of $71 168 (2010 dollars) per test administered (assuming alternative medications that eliminate all cases of ototoxicity). The annual overall impact of these potential savings is B$2.4 million in present value net costs avoided in British Columbia and $19.6 million in Canada if the test was administered to all eligible patients. The number of new cases and survival rates by type of cancer are provided in Table 4 .
Alternatives to cisplatin and otoprotectants
The current situation with respect to the availability of alternatives to cisplatin or of otoprotectants is summarized in Table 5 .
Discussion
Cisplatin is an important medication in the treatment of many pediatric cancers. However, cisplatin can lead to significant, irreversible hearing loss. A genetic test has been developed to identify those children at greatest risk of developing ototoxicity. The children that test positive have 498% chance of developing serious ototoxicity if treated with cisplatin under the current dosage protocol. We have estimated that administering this test to every pediatric cancer patient for which cisplatin is first-line therapy could potentially avoid an average of $71 168 in societal costs per tested patient, of which $4504 is health-care costs. This translates in potential present value net savings of over $2.4 million annually in British Columbia and B$19.6 million in Canada. One cost item not included in our calculations is Cochlear implants. Cochlear implants' total costs are estimated at between $70 000 and $90 000 per unit. 20, 21 However, the number of pediatric Cochlear implants done for cisplatin ototoxicity is so small-less than five cases in Canada in the last 20 years-that it has no meaningful impact on our overall estimates of cost savings.
Importantly, our estimate of potential cost savings includes only a portion of the total impact of ototoxicitythose aspects that have direct financial implications such as 13 Figures were adjusted to 0-18 years old from 0-14 years old using proportions from the research cohorts. b These only include the cases of high-risk neuroblastoma as these are the cases where cisplatin is typically used.
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health-care costs, additional educational costs or loss of productivity. To have a full picture of the impact of ototoxicity, it is necessary to identify and qualify the other effects of severe hearing loss on quality of life. These can be grouped in two categories: social impacts and psychological effects. Social impacts include limitations in communication that can lead to isolation. Children with hearing loss have fewer friends and tend to be unhappier at school. 22 In a study of children with severe hearing loss, Fellinger et al. 23 found that children with hearing impairment had a greater likelihood of developing associated emotional and behavioral problems (23; p. 420). Specifically, 'rates of deaf children with scores in the borderline or clinical range exceeded those of controls with regard to emotional problems, conduct problems and peer problems' (23; p. 418). These limitations carry over to adult life and affect the ability to develop and maintain relationships. 24 Psychological impacts include low self-confidence, frustration and mistrust of others. 20 As is the case for social impacts, psychological effects start in childhood and carry over to adulthood. 25 Severe hearing loss, when it takes place in infancy, may affect the development of attachment between the child and caregivers because caregivers typically do not have the experience of hearing loss and therefore do not know how to compensate in their communication with the infant. 25 The quality of the attachment has also been found to affect the quality of relationships later in life. 26 When ototoxicity occurs after infancy, it still leads to parenting challenges such as overprotection. 25 This impacts the ability to establish independence and emotional maturity. 25 Poor self-esteem and lower quality relationships in life often result. 25 The cumulative economic, social and psychological impacts paint a picture of individuals that often are isolated in terms of social and intimate relationships, have low selfesteem and reduced financial opportunities. In an editorial, The Lancet describes the overall impact of hearing loss in the following manner: 'Hearing-impaired adults do not fare as well economically or socially as their hearing counterparts. Vocational choice, full employment and rich social integration often elude those who are hearing impaired'. 27 The main limitation in this study is related to the assumptions that were made regarding alternative medications. As shown in Table 5 , for certain tumor types such as germ cell tumors, effective alternatives to cisplatin are available and appear to be as efficacious. 17 For other tumor types like hepatoblastoma, cisplatin is currently the most effective agent in terms of survival and thus at present such alternatives do not exist. Another therapeutic option receiving much attention is otoprotection. Amifostine has recently been shown to protect the hearing of children with brain tumors receiving cisplatin 19 and at present there are ongoing trials looking at the use of sodium thiosulfate as an otoprotectant. Genetic analysis of patients who receive otoprotectant therapy may further define a group of patients who will benefit from combined cisplatin and otoprotection strategies. The gap between current reality and our assumptions, or between current economic impact and potential one, therefore varies between the types of pediatric cancer and will continuously change over time. The assumptions about the availability of alternatives were made to avoid, in this paper, the complex issue of trade-offs. Would a family accept a 1% increase in risk of death to avoid certain deafness? Would 5% be the cutoff? Such choices involve individual psychological factors beyond the scope of this project.
A further limitation was the omission of the effects of hearing loss on quality of life from the cost calculations because of a lack of reliable measurement and valuation of these effects. We have attempted to address this limitation by describing the impact of hearing loss on quality of life but with reliable cost data these effects could be built into our model to provide an even more accurate estimate of the potential economic impact of the new test. Impact of a genetic test for cisplatin ototoxicity
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Two main research areas emerge from this study. First, as research proceeds on alternative medications, and assuming that alternatives will only progressively replace cisplatin, there is a need to better understand the impact of reduced cisplatin dosage on cancer treatment and ototoxicity, especially for those children with a genetic predisposition to ototoxicity. Second, work on protective agents can now be focused on specific children. More information is required about the effect of these agents as the trade-offs for those children can now be much more focused. Finally, this work can serve as a template for assessing the economic impact of genetic tests in other fields, thereby providing key information to decision makers charged with allocating scarce resources.
Conclusion
The analysis presented in this study provides insight into the potential economic impact of a genetic test of cisplatininduced ototoxicity susceptibility. The results suggest that the potential reduction in ototoxicity associated with the test can lead to significant health-care and societal net cost savings. On the basis of these estimates, decision makers can assess the value of future research on alternative medications and mitigating agents. As new treatments become available, the current estimate of the economic impact can be updated with the information on the costs and the efficacy of these new treatments. All cost estimates, except the therapy/support services (see below), were provided by Beth Brooks, Registered Audiologist, BC Children's Hospital and validated by two other audiologists: Anne Follows, BC Early Hearing Program Hearing Equipment Plan Manager, Regional Coordinator and Audiologist Nanaimo Health Unit Audiology Clinic and an audiologist working in sales with a private equipment supplier. These cost estimates are specific to BC but while Beth Brooks acknowledges that there are regional variations in costs and funding mechanisms, in her opinion (supported by the audiologist working in sales with a private equipment supplier), these estimates are reasonably reflective of both professional services and equipment costs across North America.
Therapy/support services
The $18 300 per year for grade 3 or 4 hearing loss for school-related services is paid for by the Ministry of Education. Ministry of Education website http:// www.bced.gov.bc.ca/specialed/special_ed_policy_manual. pdfpage ¼ 108 section H13 page 144 The $6600 per year for grade 3 or 4 hearing loss preschoolers is provided through the BC Early Hearing Program for children diagnosed with such hearing loss before 2 years old. Children diagnosed between ages 2 and 5 years have similar coverage provided through different programs-we used the same $6600 to estimate the total value of these other programs. The BC Early Hearing Program and other programs only include 2 years of direct funding. Funding for remaining years comes from public health infant/pre-school services, private insurance or out-of-pocket spending (therefore, classified as healthcare costs).
Equipment
The yearly costs for hearing aids have been calculated based on binaural amplification with replacement every 4 years including earmolds, batteries and fitting fees as follows:
* Hearing aid @ $1200 * 2 ears ¼ $2400/4 years ¼ $600/ year * Batteries @ $1 * 6/month * 2 ears *12 months ¼ $144/ year * Earmolds @ $45 * 2 ears * 3 sets/year (average for children o6 years old)=$270 * Earmolds @ $45 * 2 ears * 1 set/year (average for children 6 years old or greater) ¼ $90 * Total hearing aid cost/year: Age 0-6 years: $600 þ $144 þ $270 ¼ $1014 Age 46 years: $600 þ $144 þ $ 90 ¼ $834 * For adults, the equipment cost is the same but earmolds are needed only every 4 years with the new hearing aids; therefore, the annual cost is estimated at $766.50 ($600 for the hearing aids, $144 for batteries and $22.50 for the earmolds)
These are current costs in 2011 based on manufacturers' pricing less discounts passed on by public health services plus fitting fees. Hearing aid costs in the private sector tend to be higher ($1500-$2000 per hearing aid plus batteries and Impact of a genetic test for cisplatin ototoxicity
